MAIA price prediction by August 15 2025

The deep research logic is organized as follows: 

Okay, let's tackle this MAIA price prediction question. The user is asking for a price prediction by August 15, 2025. First, I need to check the current date in the context, which is July 1, 2025. So the prediction window is about a month and a half ahead.

Looking at the references provided, there's a lot of recent news about MAIA Biotechnology. They've entered into a clinical master supply agreement with Roche for cancer treatments, which is a big deal. Also, they've done some stock purchase agreements with Prevail Partners to raise funds for Phase 3 studies. The stock price on July 1, 2025, is $1.95, up 8.31% from the previous day. The closing price on July 1 is $1.9495 .

The technical analysis from the query shows a bearish trend for 18 days, with a continuation probability of 53% . The resistance level as of July 1 is $1.90, and the trading volume is 2.16 million shares . The stock has a market cap of around $59.387 million . The earnings release date is set for August 8, 2025 , which is just a week before the user's target date of August 15.

The user's profile mentions they're interested in short-term trading, breakout penny stocks, and high volume. They also looked into Gnln's price prediction by July 3rd, 2025. So, the user is likely looking for a quick turnaround or potential breakout around the earnings date.

Now, considering the recent news, the partnership with Roche could be a catalyst. Positive clinical trial results or updates around the Phase 3 studies might drive the stock up. However, the technical indicators are bearish, which might indicate some short-term pressure. The resistance level at $1.90 is just below the current price, so if the stock breaks above that, it could see some upward momentum.

The earnings on August 8 could be a key event. If the results are positive, especially regarding the Phase 2 and Phase 3 trials, the stock might surge. But if there are any delays or negative data, it could drop. The user's interest in high volume stocks aligns with the recent trading volume spike, which might indicate increased liquidity and potential for volatility.

Putting this together, the prediction needs to balance the upcoming earnings, the recent partnerships, and the technical setup. The stock is near a resistance level, and with earnings around the corner, there's a high chance of volatility. The user is likely looking for a short-term trade setup, so the prediction should highlight the potential breakout above $1.90 and the earnings catalyst.

I should structure the answer with a conclusion first, then break down the analysis into key factors like upcoming events, technical setup, and market context. Make sure to cite the references properly and include the visualization for the price trend forecast. Also, since the user is into short-term trading, emphasize the time-sensitive factors like the earnings date and the recent news.

**Conclusion** 🎯
Based on the latest data and market context, **MAIA Biotechnology (MAIA.A)** is positioned for **short-term volatility** with a **potential breakout** around its resistance level of **$1.90** by August 15, 2025. The stock’s **upcoming earnings release** (August 8, 2025) and **recent strategic partnerships** (e.g., Roche collaboration) could act as key catalysts for price movement. However, the **bearish trend** and **mixed technical indicators** suggest caution for short-term traders.

---

### 📊 **Key Analysis**
#### 1. **Upcoming Catalysts**
| Catalyst | Impact | Timeline |
|----------|--------|----------|
| **Earnings Release** | Potential volatility; focus on Phase 2/3 trial updates | August 8, 2025 |
| **Roche Partnership** | Positive sentiment boost; clinical trial synergy with atezolizumab | Ongoing |
| **Prevail Partners Funding** | Liquidity boost for Phase 3 studies; $587k raised | Completed (June 2025) |

#### 2. **Technical Setup**
| Metric | Current Data | Implication |
|--------|--------------|-------------|
| **Price Trend** | Bearish (18-day duration), 53% continuation probability | Short-term downside risk |
| **Resistance Level** | $1.90 (as of July 1, 2025) | Breakout above $1.90 could trigger upside momentum |
| **Volume** | 2.16M shares (July 1, 2025) | High liquidity for short-term trading |

#### 3. **Market Context**
| Context | Data | Analysis |
|---------|------|----------|
| **Stock Performance** | Last Price: $1.95 (7.63% gain on July 1, 2025) | Recent bullish momentum but near resistance |
| **Market Cap** | $59.38M (as of July 1, 2025) | Small-cap volatility potential |
| **Analyst Activity** | No recent price targets or revisions | Lack of institutional coverage; rely on fundamentals |

---

### 📉 **Risks & Opportunities**
| Risk | Opportunity |
|------|-------------|
| **Bearish Trend** | Potential upside if earnings beat expectations |
| **High Debt** | Liquidity from Prevail Partners ($587k) supports R&D |
| **No Revenue** | FDA approval (2026) could unlock long-term growth |

---

### 📊 **Price Prediction**
| Scenario | Probability | Price Range |
|----------|-------------|-------------|
| **Bearish Continuation** | 53% | $1.70–$1.85 |
| **Bullish Breakout** | 47% | $1.90–$2.10 |

**Final Call**: MAIA.A is **neutral to bullish** with a **target range of $1.85–$2.00** by August 15, 2025. The **earnings release** and **Roche partnership** are critical watchpoints for short-term traders.